Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13;11(5):875.
doi: 10.3390/diagnostics11050875.

Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update

Katya Prakash  1 , Aditya Chandorkar  2 , Kapil K Saharia  1
Affiliations
Review

Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update

Katya Prakash et al. Diagnostics (Basel). .

Abstract

Cytomegalovirus (CMV) is one of the most important opportunistic infections in solid organ transplant (SOT) recipients. However, current techniques used to predict risk for CMV infection fall short. CMV-specific cell mediated immunity (CMI) plays an important role in protecting against CMV infection. There is evidence that assays measuring CMV-CMI might better identify SOT recipients at risk of complications from CMV compared to anti-CMV IgG, which is our current standard of care. Here, we review recently published studies that utilize CMV-CMI, at various points before and after transplantation, to help predict risk and guide the management of CMV infection following organ transplantation. The evidence supports the use of these novel assays to help identify SOT recipients at increased risk and highlights the need for larger prospective trials evaluating these modalities in this high-risk population.

Keywords: CD4+ T cell; CD8+ T cell; CMV; ELISA; ELISpot; cell-mediated immunity; flow cytometry; solid organ transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The sponsor had no role in the design, execution, interpretation, or writing of the study.

References

    1. Limaye A.P., Bakthavatsalam R., Boeckh M., Kim H.W., Randolph S.E., Halldorson J.B., Healey P.J., Kuhr C.S., Levy A.E., Perkins J.D., et al. Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. Transplantation. 2006;81:1645–1652. doi: 10.1097/01.tp.0000226071.12562.1a. - DOI - PubMed
    1. Bosch W., Heckman M.G., Diehl N.N., Shalev J.A., Pungpapong S., Hellinger W.C. Association of Cytomegalovirus Infection and Disease with Death and Graft Loss After Liver Transplant in High-Risk Recipients. Am. J. Transplant. 2011;11:2181–2189. doi: 10.1111/j.1600-6143.2011.03618.x. - DOI - PubMed
    1. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., Pescovitz M.D., Valganciclovir Solid Organ Transplant Study Group Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients. Am. J. Transplant. 2004;4:611–620. doi: 10.1111/j.1600-6143.2004.00382.x. - DOI - PubMed
    1. Kotton C.N., Kumar D., Caliendo A.M., Huprikar S., Chou S., Danziger-Isakov L., Humar A. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102:900–931. doi: 10.1097/TP.0000000000002191. - DOI - PubMed
    1. Razonable R.R., Humar A. Cytomegalovirus in Solid Organ Transplant Recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 2019;33:e13512. doi: 10.1111/ctr.13512. - DOI - PubMed